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doi:10.1016/j.jtcvs.2006.05.070bjective: N-acetylcysteine, a potent anti-inflammatory and antioxidant agent, is
nown to decrease the production of reactive oxygen species after cardiac surgery.
he objective of this study was to evaluate the effects of intravenous N-acetylcys-
eine on clinical and biochemical outcomes after coronary artery bypass surgery
ith cardiopulmonary bypass.
ethods: One hundred patients (mean age 60.5 years, range 43-78 years, 89% male)
ndergoing coronary artery bypass grafting at the Montreal Heart Institute were
andomized to receive either N-acetylcysteine (600 mg orally the day before and the
orning of the operation, a bolus of 150 mg/kg of intravenous N-acetylcysteine
efore skin incision, followed by perfusion at 12.5 mg · kg1 · h1 over 24 hours;
 50) or placebo (n  50). The patients and clinical team were blinded to group
ssignments. Preoperative characteristics were similar between the two groups.
ostoperative clinical data (death, myocardial infarction, low-output syndromes,
rrhythmias, bleeding, transfusion requirements, and intensive care unit and hospital
engths of stay) and biochemical markers (creatine kinase MB, troponin T, creati-
ine, hemoglobin, and platelet levels) were evaluated serially over 4 days.
esults: Clinical outcomes were not significantly different between the two groups
ith regard to the incidence of death, myocardial infarction, bleeding, transfusion
equirements, intubation time, and hospital length of stay. No differences were
ound in postoperative biochemical markers (troponin T, creatine kinase MB,
reatinine, hemoglobin, and platelets) between the groups. No differences were
bserved between the groups in interleukin-6 production (P  not significant).
onclusions. Prophylactic use of N-acetylcysteine in patients undergoing coronary
rtery bypass grafting with cardiopulmonary bypass does not lead to improvement
n clinical results or biochemical markers. Further strategies to decrease reperfusion
njury should be devised.
he role of cardiopulmonary bypass (CPB) in the pathophysiology of events
after cardiac surgery is well established but incompletely understood. The
advent of off-pump coronary artery surgery, although showing some benefits
n population subsets, has not led to significant improvements as was expected by
voiding CPB. Therefore, various strategies are needed to counteract the deleterious
ffects associated with on-pump surgery, which include myocardial ischemia-
eperfusion and protection from the systemic reaction affecting the neurologic,
enal, and hematologic systems. End-organ damage is attributed to the inflammatory
eaction after CPB and to a significant oxidative stress resulting from the ischemia-
eperfusion cycle. Indeed, reactive oxygen species (ROS), such as superoxide
adical (O2), hydroxyl radical (OH), hydrogen peroxide (H2O2), and peroxyni-
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CSPrite (ONOO), have all been incriminated in the pathogen-
sis of post-CPB ROS-mediated myocardial and systemic
tructural and functional damage.
N-acetylcysteine (NAC) is an antioxidant agent widely
nown as an antidote for acetaminophen intoxication. Re-
ently, it has gained renewed interest and wide use because
f its role in the minimization of reperfusion injury after
cute myocardial infarction and its protective effects on
enal function in diabetic patients after contrast injection.1
AC acts in several ways, namely, by neutralizing oxygen
adicals, by protecting the cellular membrane through its
ulfhydril groups, and by preserving endothelial function.2
everal reports have previously studied the effects of NAC
fter CPB in patients having cardiac surgery, which showed
reduction in markers of ROS-mediated myocardial in-
ury.3-5 The purpose of the present study was to analyze the
mpact of NAC supplementation before cardiac surgery
ith CPB on clinical and biochemical markers in a random-
zed, placebo-controlled, double-blind trial in patients un-
ergoing primary coronary artery bypass grafting (CABG).
he primary hypothesis was that NAC supplementation
ould lead to improved myocardial protection after CPB in
atients undergoing primary CABG surgery. The secondary
ypothesis was that NAC supplementation would lead to
ess postoperative bleeding and less renal dysfunction.
atients and Methods
atient Population
prospective, randomized, placebo-controlled, double-blind
tudy was conducted at the Montreal Heart Institute after approval
rom the local ethics committee and written informed consent from
he patients. Between January 2003 and March 2004, 100 patients
89 men and 11 women; mean age 60.6  7.6 years) undergoing
rimary CABG with CPB were randomly assigned to receive NAC
efore surgery (group 1; n  50) or placebo (group 2; n  50).
atients in group 1 received 600 mg of oral NAC the day before
nd the morning of the operation. Additionally, patients in group 1
eceived a bolus of 150 mg/kg of intravenous NAC over a 15-
inute period immediately before skin incision, followed by per-
usion at 12.5 mg · kg1 · h1 over 24 hours. Patients in the control
roup (group 2) received oral and intravenous placebo throughout
his period. Oral and intravenous preparations were similar to those
Abbreviations and Acronyms
CABG  coronary artery bypass grafting
CK-MB creatine kinase
CPB  cardiopulmonary bypass
ICU  intensive care unit
IL-6  interleukin 6
NAC  N-acetylcysteine
NS  not significant
ROS  reactive oxygen speciesf the NAC group. Exclusion criteria were emergency operations, p
The Journal of Thoracic and Cardiovascular Surgery ● Januarcute myocardial infarction within fewer than 3 weeks, prior
ardiac surgery, age older than 80 years, ejection fraction less than
0%, and concomitant procedures. The primary end point was the
ean postoperative release of cardiac troponin T levels between
he two groups (1, 2, 4, 8, 12, and 24 hours postoperatively, then
, 3, and 4 days postoperatively). Secondary end points included
he rate of myocardial infarction (as defined by creatine kinase
CK-MB) level 50 and/or new Q wave on electrocardiogram in
given territory), renal function (creatinine), bleeding, low cardiac
utput syndromes, arrhythmias, and mean levels of CK-MB.
linical Protocol
ll patients underwent CABG with CPB under moderate hypo-
hermia (34°C). Tepid antegrade blood cardioplegia (4:1 solution
t 28°C) was used in all cases. No hypothermia and no retrograde
ardioplegia were used. No topical cooling methods were used.
he left internal thoracic artery was used in all cases but 1 in group
. Aprotinin (Trasylol; Bayer Inc, West Haven, Conn) was admin-
stered in all cases according to the full-dose Hammersmith pro-
ocol.6 This institutional policy represented standard of care at the
ontreal Heart Institute during the study period, although it has
hanged after recent reports on the effects of aprotinin on renal
unction.
tudy Protocol
everal variables were evaluated after surgery. Clinical variables
ncluded death, myocardial infarction, low cardiac output syn-
rome (postoperative intra-aortic balloon pump insertion or vaso-
ressive medication requirements for 30 minutes), bleeding,
ransfusion requirements, cerebrovascular accidents, arrhythmias
supraventricular and ventricular), atrial fibrillation, intubation
ime, and intensive care unit (ICU) and hospital lengths of stay. All
lectrocardiograms were interpreted by 2 independent observers
ICU physicians) who were blinded to the study groups. Myocar-
ial infarction was defined as a new Q wave based on the Minne-
ota Code or as maximum perioperative CK-MB levels at any time
oint greater than 50 units. Biochemical markers included mean
ardiac troponin T and CK-MB levels (1, 4, 8, 12, and 24 hours
ostoperatively, then 2, 3, and 4 days postoperatively), serum
reatinine levels (preoperatively and daily postoperatively until
ay 5), hemoglobin and platelet levels, and alveolocapillary gra-
ients (preoperatively and 1, 3, and 6 hours postoperatively). All
ata were collected by an independent research nurse assigned to
his research study and blinded to the groups. Regarding cardiac
roponin, CK-MB units, and serum creatinine, the mean levels at
ach time point were evaluated and compared between the two
roups.
Furthermore, so that the anti-inflammatory effects of NAC in
his patient population could be evaluated, blood was withdrawn
rom the coronary sinus circulation of 12 patients and levels of
nterleukin-6 (IL-6) were quantified by high-sensitivity enzyme-
inked immunosorbent assay (Quantikine HS; R&D Systems, Min-
eapolis, Minn) at various time points (preoperatively, 1 hour after
ypass in the coronary sinus, and then 4, 8, 12, and 24 hours
ostoperatively in the systemic venous circulation).
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Ptatistical Analysis
ll data were analyzed with the help of the Biostatistics Depart-
ent at the Montreal Heart Institute. 2 analyses were performed
or all categorical variables. Repeated analysis of variance mea-
ures were used to evaluate the postoperative differences over time
f troponin, CK-MB, creatinine, hemoglobin, platelets, and alveo-
ocapillary gradients between the two groups. For troponin and
K-MB analysis, a logarithmic transformation of variables was
erformed to correct for their skewed distribution. The study
ample size was determined to show a 25% reduction of the
verage levels of postoperative troponin T levels in patients who
ere administered NAC with an -error of 5% and a  of 20%
ielding a power of 80%.
esults
reoperative Data
here were no differences between the two groups in terms of
ender, age, New York Heart Association functional class, left
entricular ejection fraction, distribution of coronary disease,
he incidence of previous myocardial infarction, or unstable
ngina (P  not significant [NS]) (Table 1). The two groups
ere also similar in terms of preoperative oral medications
ABLE 2. Intraoperative patient characteristics
atient characteristics
NAC group
(n  50)
Control group
(n  50) P value
o. of grafts 3.0 3.1 .6
ITA-LAD (%) 100 98 .9
ortic crossclamp time (min) 42 18 43 19 .9
uration of CPB (min) 71 23 70 24 .8
lood losses (mL) 419 240 341 171 .07
ostop cardiac index 2.5 0.7 2.6 0.6 .4
AC, N-acetylcysteine; LITA, left internal thoracic artery; LAD, left anterior
ABLE 1. Preoperative patient characteristics
atient characteristics
NAC group
(n  50)
Control group
(n  50)
P
value
ge 59.8  7.8 61.3  7.4 .3
ex (% male) 86 92 .3
YHA III-IV/IV (%) 39 50 .7
nstable angina (%) 44 44 .9
revious MI (%) 33 46 .2
ardiac output 2.5  0.7 2.2  0.5 .2
-blockers (%) 88 76 .1
alcium-channel blockers (%) 44 42 .8
CE inhibitors (%) 56 48 .4
eft main coronary stenosis (%) 22 26 .7
hree-vessel disease (%) 82 82 .9
V dysfunction (%) 8 12 .3
AC, N-acetylcysteine; NYHA, New York Heart Association; MI, myocar-
ial infarction; ACE, angiotensin-converting enzyme; LV, left ventricular.sescending; CPB, cardiopulmonary bypass.
The Journal of Thora-blockers, calcium-channel blockers, and angiotensin-
onverting enzyme inhibitors; P  NS).
ntraoperative Data
o differences were found between the two groups in terms
f number of grafted arteries, left internal thoracic artery
se, CPB time, crossclamp time, or blood losses (P  NS)
Table 2). One patient in group 1 underwent a coronary
ndarterectomy on the left anterior descending artery for
everely calcified plaques.
nti-inflammatory Effect
aseline IL-6 levels were similar between the two groups (P
NS). There were no demonstrable differences in coronary
inus IL-6 levels between the groups 1 hour after discon-
inuation of CPB (180.6  203.7 in the NAC group versus
87.5  78.8 in the placebo group; P  NS). Although
verage IL-6 levels at 4, 8, 12, and 24 hours postoperatively
ere lower in the NAC group, these differences did not
each statistical significance (Figure 1).
yocardial Protection
here were 3 deaths in the NAC group. No deaths occurred in
he placebo group (P NS). Three patients in the NAC group
ad a postoperative myocardial infarction (1 of whom had an
ndarterectomy on the left anterior descending coronary artery)
ersus 1 patient in the placebo group (P .5). Troponin levels
ere not statistically different between groups at 1, 4, 8, 12,
nd 24 hours nor at 2, 3, and 4 days postoperatively (Figure 2).
o significant differences were noted for CK-MB levels at the
igure 1. IL-6 levels at different time points between NAC and
lacebo groups (P  NS). IL-6, interleukin-6; NAC,
-acetylcysteine.ame time intervals (Figure 3).
cic and Cardiovascular Surgery ● Volume 133, Number 1 9
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CSPenal Function
ostoperative creatinine levels did not show any differences
etween the two groups (P  NS) (Figure 4).
linical Outcomes
o statistically significant differences were noted either for
emoglobin levels, platelet levels, or alveolocapillary gra-
ients between the two groups (P  NS). The incidence of
ow cardiac output, surgical re-exploration, atrial fibrilla-
ion, and ventricular arrhythmias was not statistically dif-
erent between the two groups (P  NS). Also, no statisti-
ally significant differences were found in terms of
ntubation time and hospital length of stay (P  NS) (Table
). No cases of cerebrovascular accidents were reported.
igure 2. Comparison of postoperative troponin T levels between
AC group and placebo. NAC, N-acetylcysteine.
igure 3. Comparison of postoperative CK-MB levels between
AC group and placebo. CK-MB, creatine kinase; NAC, N-ace-
ylcysteine. N
0 The Journal of Thoracic and Cardiovascular Surgery ● Januaiscussion
he results of the present study show that perioperative
ntravenous NAC administration in patients undergoing pri-
ary CABG with CPB does not improve clinical or bio-
hemical outcomes after surgery. Myocardial protection and
enal function were unchanged despite NAC supplementa-
ion perioperatively.
Previous research shows histologic evidence of ischemia-
eperfusion injury in up to 25% of pathologic specimens of
atients having died after cardiac surgery with cardioplegic
rrest. Therefore, reduction of the ischemia-reperfusion reac-
ion and its cellular and structural consequences after CABG is
n inherent goal and has been the focus of much research in the
ast 20 years. Ischemia may occur in patients with unstable
ngina awaiting surgery, it can occur at the time of induction,
s well as during the period of aortic crossclamping. Several
igure 4. Comparison of serum creatinine levels between NAC
roup and placebo (mol/L). NAC, N-acetylcysteine. POD, Post-
perative day.
ABLE 3. Postoperative patient characteristics
atient characteristics
NAC group
(n  50)
Control group
(n  50) P value
eath (30 days) 3 0 .1
yocardial infarction (n) 3 1 .2
ow-output syndrome (n) 2 0 .2
upraventricular arrhythmia (%) 34 24 .4
trial fibrillation (%) 7 12 .7
entricular arrhythmia (%) 12 10 .7
urgical re-exploration (n) 4 1 .2
ntubation (h)* 6.5 8.6 .5
ospital length of stay (d) 5.4  2.3 5.3  2.5 .7AC, N-acetylcysteine. *Intubation times expressed as median.
ry 2007
ss
t
a
s
c
b
i
t
i
t
i
r
i
b
s
t
a
p
a
t
s
d
f
a
b
b
t
s
p
o
N
t
M
a
v
p
t
b
w
t
2
d
t
t
i
a
i
f
r
t
j
a
w
4
s
n
a
s
v
w
c
p
w
i
a
d
i
i
t
s
t
p
l
C
I
u
i
c
p
e
r
s
r
s
a
R
El-Hamamsy et al Cardiopulmonary Support and Physiology
CS
Ptrategies have been tested both experimentally and in clinical
ettings, including different routes of cardioplegia administra-
ion,7 different temperatures,8 and supplementation with L-
rginine,9 vitamin C,10 and allopurinol.11 However, no single
trategy has consistently or significantly altered postoperative
linical outcomes.
NAC was first suggested as an additive to cardioplegia
y Menasché and associates in 1992.12 They showed an
mprovement in postarrest recovery of function, presumably
hrough an enhancement of the reduced thiol pool, which
ncreases the capacity of reperfused myocardium to handle
he postischemic burst of free radical production.
The absence of observed benefit is somewhat disappoint-
ng considering the body of literature showing positive
esults pertaining to reduction of ROS and mediators of
nflammatory reaction.3-5,13-15 Indeed, recent publications
y Fischer and colleagues4 showed a reduction in oxidative
tress, myocardial edema, and cardiomyocyte apoptosis af-
er CPB. These findings were attributed to the powerful
ntioxidant and anti-inflammatory effects of NAC. In most
rotocols, NAC was added to the pump prime or was
dministered immediately before CPB initiation and main-
ained for 60 minutes after its discontinuation. In the present
tudy, NAC was administered as 600 mg of oral NAC the
ay before the operation and the morning of the operation,
ollowed by intravenous administration before skin incision
nd for 24 hours postoperatively. The oral dosing regimen is
ased on the dosing regimen used for renal protection
efore angiographic procedures.2 The decision to start pa-
ients on NAC preoperatively was based on the observations
uggesting that ROS are present before CPB initiation,
robably owing to anesthesia induction, to surgical trauma,
r both. Thus, as suggested by Tossios and coworkers,3
AC application should begin before anesthesia induction
o yield maximal benefit of its ROS-scavenging properties.
oreover, considering the short half-life of NAC estimated
t 2.2 hours,16 NAC was maintained as a continuous intra-
enous infusion for 24 hours after CPB to ensure prolonged
rotection from oxidative injury after reperfusion. Despite
hese modifications, no clinical or biochemical myocardial
enefit was observed. Moreover, no statistical differences
ere observed between the groups in IL-6 levels at different
ime points after CPB discontinuation and during the initial
4 postoperative hours. This absence of observed statistical
ifference comes despite a more aggressive NAC adminis-
ration protocol than used in previous studies.
Acute renal failure after CABG is a frequent complica-
ion occurring in up to 7% of patients.17 Acute renal failure
s an independent factor associated with increased mortality
fter CABG.18 Therefore, all strategies that help reduce the
ncidence of acute renal failure after CABG are beneficial
or patients’ prognosis. NAC has been used increasingly
ecently after reports of renal function preservation in pa-
The Journal of Thoracients undergoing radiographic procedures with contrast in-
ection.3 Although in the present study patients were not at
particularly high risk of acute renal failure, no differences
ere noted in the incidence of renal dysfunction over a
-day period after CPB in the present study population. This
uggests that the etiology of post-CPB renal dysfunction is
ot as much a matter of ischemia-reperfusion injury as it is
question of maintaining adequate renal perfusion pres-
ures throughout CPB and adequate hemodynamic and
olemic states after surgery. In fact, in another study in
hich NAC prophylaxis was used in patients undergoing
ardiac surgery, looking at renal function as the primary end
oint, no differences in the incidence of acute renal failure
ere noted postoperatively.19
The present study has several limitations. First, accord-
ng to institutional policy, all patients received full-dose
protinin. Although it could have limited the power to
iscern the true difference in bleeding between the groups,
t did not, however, introduce a bias because it was admin-
stered equally to all patients. Furthermore, despite a trend
owards less IL-6 production in patients receiving NAC, no
tatistically significant differences were observed between
he groups. However, on the basis of prior studies, the NAC
rotocol used in this study was more aggressive and pro-
onged (24-hour infusion).
onclusions
n the present study, prophylactic use of NAC in patients
ndergoing primary CABG with CPB does not lead to
mproved myocardial protection, renal function, or bio-
hemical markers. Furthermore, NAC administration in this
atient population did not exert a significant anti-inflammatory
ffect. However, considering the positive and encouraging
esults of more fundamental research on its use in a CPB
etting, further strategies to decrease the impact of ischemia-
eperfusion injury should be sought, by combining different
trategies, by targeting a specific population, or by modifying
dministration strategies.
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